US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.32 against a street estimate of -0.19 — a miss of 68.4%.
Analysts rate Tilray Inc a buy (3 buy, 7 hold, 0 sell out of 10) with an average price target of $5.89.
CONFIDENT Tilray delivered record Q1 revenue and gross profit, with BrewDog turning profitable and international cannabis growing, while cannabis revenue declined and adjusted EBITDA fell year over year. Q1 FY27 International growth was led by Germany, the UK, and Portugal-supported medical cannabis operations; Canada faced planned product transitions and supply constraints. Analysts pressed management on BrewDog’s profitability, Canadian cannabis weakness, Carlsberg’s potential, M&A priorities, and German reimbursement changes. Management emphasized operational stabilization, deliberate inventory allocation, and growth from the global platform, but provided no quantified Carlsberg upside. 2026-10-08…
Full summary in the app.
| Fund | Stake |
|---|---|
| 1 NORTH WEALTH SERVICES LLC | 0.00% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tilray Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.